| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2970171 | The Journal of Heart and Lung Transplantation | 2015 | 7 Pages |
Abstract
An increasing number of patients receiving HTx under 1A listing are supported with CF-LVADs. DRCs are steadily increasing, with most of them from the B2 category. Post-HTx survival in DRC+ group is inferior, primarily for the B2 category. The benefits of CF-LVADs for patients awaiting HTx need to be weighed against the development of DRCs with subsequently inferior post-HTx survival.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Mohammed A. MD, Luke G. MS, Vigneshwar MD,